Does Dr. WILLIAM WHITE have financial conflicts of interest?

Dr. WILLIAM WHITE (MD) has received a total of $2,034,478 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,644,790 in personal promotional payouts (consulting, meals, travel) and $389,688 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. WILLIAM WHITE?

According to CMS Open Payments data, Dr. WILLIAM WHITE received funding from SUMITOMO PHARMA AMERICA ($342,445), UCB SA ($260,130), and TAKEDA PHARMACEUTICALS U.S.A ($250,149).

Does Dr. WILLIAM WHITE receive research grants or speaking fees?

Dr. WILLIAM WHITE has received $1,644,790 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $389,688 in clinical research grants.

DR. WILLIAM WHITE

MDReal-Time Hydrated

Specialty: Internal Medicine, Hypertension Specialist

Practice Location: FARMINGTON, CT 06030

NPI Number: 1760489546

LIFETIME INDUSTRY VALUE

$2,034,478

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. WHITE is a verified Internal Medicine, Hypertension Specialist practitioner based in FARMINGTON, CT.

Between 2021 and 2025, Dr. WHITE had an overall industry promotional and research financial footprint of $2,034,478 as recorded in the federal CMS Open Payments database.

$1,644,790 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$389,688 was allocated to sponsored clinical trials and medical research activities.

Dr. WHITE's primary funding source is SUMITOMO PHARMA AMERICA, which accounts for $342,445 (representing 16.8% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

SUMITOMO PHARMA AMERICA

Rank 1

$342,445

16.8%

UCB SA

Rank 2

$260,130

12.8%

TAKEDA PHARMACEUTICALS U.S.A

Rank 3

$250,149

12.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.